HBW InsightEarly evidence suggests US Food and Drug Administration Commissioner nominee Martin Makary could be a more “conventional” agency leader than others in President Trump’s second administration. Makary i
Pink SheetEarly evidence suggests US Food and Drug Administration Commissioner nominee Martin Makary could be a more “conventional” agency leader than others in President Trump’s second administration. Makary i
ScripJohnson & Johnson announced on 21 March that it will invest $55bn in US manufacturing facilities and other domestic infrastructure over the next four years – the length of Donald Trump’s president
ScripCargo Therapeutics’ decision to end all development for its allogeneic cell therapy technology platform and its cancer cell therapy candidates is not the kind of news the biopharmaceutical sector need